Senescent cells stop dividing but refuse to clear out. They sit in tissue, secrete inflammatory signals, and accumulate as you age. In mice, removing them extends healthy lifespan and reverses several age-related changes. That result is genuinely striking, and it is the engine behind every senolytic product now on sale.
The gap between that mouse work and a capsule is wider than most product pages admit.
The Verdict
What senolytics are supposed to do
A senolytic is a compound that selectively kills senescent cells while leaving healthy ones alone. Senescent cells resist normal cell death signals, and senolytics work by interfering with the survival pathways they depend on.
The strategy is deliberately intermittent. Because these compounds kill cells rather than adjusting a process, the tested approach is a short high dose, then a gap of weeks while the cells slowly re-accumulate. Researchers call this hit-and-run dosing. It matters commercially, because it is not how consumer senolytics are usually sold.
The compounds, and what each one actually has behind it
| Compound | What it is | Human evidence | The practical catch |
|---|---|---|---|
| Dasatinib | Prescription cancer drug (tyrosine kinase inhibitor) | Used in most published human senolytic trials, always paired with quercetin | Prescription only. Real toxicity profile. Not obtainable as a supplement. |
| Quercetin | Flavonoid, sold as a supplement | Studied almost exclusively as the partner to dasatinib, not alone | Poor oral bioavailability. Trial doses are far above typical supplement servings. |
| Fisetin | Flavonol found in strawberries, sold as a supplement | Cleared senescent cells in mice; human trials are ongoing and mostly unpublished | Poor oral bioavailability. Consumer doses rarely match trial protocols. |
| Piperlongumine | Plant alkaloid from long pepper | Preclinical only | No human trial data. |
| UBX0101 | Purpose-built senolytic drug | Failed to beat placebo in a phase 2 knee osteoarthritis trial | The clearest evidence that clearing senescent cells is harder than the mouse work suggested. |
The human trials, read carefully
Four studies define what is actually known. Two are small and encouraging, one is a clean failure, and the rest have not reported.
| Study | Who | Intervention | Result | The limitation |
|---|---|---|---|---|
| Justice 2019 | 14 adults with idiopathic pulmonary fibrosis | Dasatinib + quercetin, 3 weeks | Physical function measures including walk distance improved | Open-label, no control group, 14 people |
| Hickson 2019 | 9 adults with diabetic kidney disease | Dasatinib + quercetin, 3 days | Senescent cell burden in fat tissue and skin fell, alongside some circulating inflammatory signals | Nine people, no control group, no clinical endpoint |
| Unity phase 2 (UBX0101) | Adults with knee osteoarthritis | Single injection into the joint | No benefit over placebo | A well-run trial of a purpose-built drug that did not work |
| Ongoing fisetin trials | Older adults, various conditions | Intermittent high-dose fisetin | Results largely not yet published | Read them when they report, not before |
The 2019 pulmonary fibrosis and diabetic kidney disease studies are frequently cited as proof that senolytics work in humans. They enrolled 14 and 9 people respectively, ran without control groups, and studied people with serious disease. They are proof that the approach is worth testing further, which is what their authors said.
The UBX0101 result deserves more attention than it gets. A company built a senolytic specifically for osteoarthritis, injected it straight into the affected joint, and ran a proper placebo-controlled phase 2. It did not beat placebo. When a well-designed test of the strongest version of an idea fails, that is information, and it should temper any claim built on a supplement version of the same idea.
Where to read the trials yourself
- Justice et al. 2019, EBioMedicine: dasatinib plus quercetin in 14 people with idiopathic pulmonary fibrosis, open-label.
- Hickson et al. 2019, EBioMedicine: senescent cell burden in 9 people with diabetic kidney disease.
- Unity Biotechnology: the company that developed UBX0101 and discontinued the programme after its phase 2 osteoarthritis result.
- The Kirkland laboratory at Mayo Clinic: the source of much of the underlying senescence research these products cite.
The gaps between the science and the shelf
| The gap | What it means for you |
|---|---|
| No way to measure your senescent cell burden | The trials that measured senescence used fat or skin biopsies analysed in research laboratories. No consumer test exists. You cannot establish a baseline, and you cannot tell whether anything happened. |
| Consumer doses do not match trial doses | Published protocols used gram-level quercetin alongside prescription dasatinib, given for two or three consecutive days. A daily capsule of a few hundred milligrams is a different intervention with a shared ingredient name. |
| The hit-and-run schedule is rarely replicated | Senolytic logic is intermittent by design: clear the cells, stop, let them re-accumulate. Most consumer products are sold as a daily supplement, which is the opposite of the tested schedule. |
| Bioavailability is the unsolved problem | Quercetin and fisetin are both poorly absorbed. Formulation claims about liposomal or phospholipid delivery are largely untested against the outcome that matters. |
| Trial populations were sick, not healthy | The published human work enrolled people with pulmonary fibrosis, kidney disease or cognitive impairment. Whether a healthy 45-year-old carries enough senescent cell burden to benefit is unstudied. |
Where this sits against better-evidenced options
Senolytics occupy the most speculative tier of the longevity supplement market, alongside NAD+ precursors. Both categories share a defining weakness: no consumer test exists for the mechanism they target, so the purchase cannot be evaluated after the fact.
That is worth weighing against the interventions that do come with a readout. An omega-3 index under 4% is measurable, correctable, and re-testable in three months. Fasting insulin responds to training and weight change within weeks. Creatine produces strength and lean mass changes you can observe. Each of those closes a loop. A senolytic capsule cannot, at any price.
Our position on this category is deliberately conservative, and it will change when the fisetin trials report. If a properly powered, placebo-controlled trial in healthy older adults shows a functional benefit, the evidence tier moves. Until then the reasonable read is that senolytics are an active and legitimate research area, and a premature consumer product.
When to involve a physician
- Before combining quercetin with prescription medication. Quercetin inhibits several drug-metabolising enzymes and interacts with blood thinners and some blood pressure medicines.
- Any interest in dasatinib. It is a prescription drug with a serious toxicity profile and requires monitoring that only supervised use provides.
- Existing kidney or liver disease, given how these compounds are cleared and that the trial populations were closely monitored.
- Any planned surgery, because of the bleeding and platelet considerations attached to several compounds in this class.
Frequently Asked Questions
Do senolytic supplements work?
No senolytic supplement has been shown to improve a health outcome in healthy adults. The compound with the strongest human data is dasatinib combined with quercetin, and dasatinib is a prescription cancer drug rather than a supplement. Consumer fisetin and quercetin products are sold on the strength of mouse studies and a small number of trials in people with specific diseases.
What is a senescent cell?
A senescent cell is one that has permanently stopped dividing but has not been cleared away. It stays metabolically active and secretes inflammatory signals, a pattern researchers call the senescence-associated secretory phenotype. These cells accumulate with age, and in mice, removing them extends healthy lifespan. Whether removing them helps humans is the open question the trials are trying to answer.
Is fisetin better than quercetin?
Neither has been shown superior in humans, because no trial has compared them directly at matched doses. Fisetin cleared senescent cells more efficiently than quercetin in mouse screening work, which is why it attracted attention. Both share the same practical problem: poor oral absorption, and no way to confirm the effect in a person.
Why did UBX0101 fail?
UBX0101 was a purpose-built senolytic injected directly into the knee joint, and in a phase 2 trial it did not outperform placebo for osteoarthritis pain. The failure is informative because it removed the usual excuses. The compound was designed for the job, delivered to the target tissue, and tested properly. It suggests that clearing senescent cells in humans is harder, or less useful in that setting, than the mouse data implied.
Can I test whether senolytics are working?
Not with anything available to consumers. Research trials assess senescent cell burden through fat or skin biopsies with laboratory staining, or through panels of circulating senescence-associated proteins that have no clinical reference ranges. Biological age tests do not measure senescence. Some inflammatory markers such as hsCRP move for many reasons and cannot be attributed to senescent cell clearance.
Are there risks to taking dasatinib for longevity?
Dasatinib is a prescription tyrosine kinase inhibitor with a documented toxicity profile that includes fluid retention around the lungs and heart, bleeding risk, and bone marrow suppression. It is prescribed for leukaemia under haematology supervision with monitoring. Obtaining it outside that context removes the monitoring that makes its use defensible, and this is a conversation for a physician who knows your full history.